Home › Funds › ADAR1 Capital Management, LLC › URGN

ADAR1 Capital Management, LLC position in URGN

UROGEN PHARMA LTD · Health Care

ADAR1 Capital Management, LLC reported holding 369,785 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$15.0M, representing 0.82% of its reported portfolio and ranking #28 among its reported holdings. ADAR1 Capital Management, LLC has disclosed URGN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)369.79K sh
Reported value held$15.02M
Portfolio Weight0.82%
First reportedQ2 2025
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's URGN position evolved

ADAR1 Capital Management, LLC first disclosed a stake in URGN in Q2 2025 at 10,000 shares (US$137K). The position peaked in Q3 2026 at 369,785 shares, worth US$15.0M. Across 6 filings, ADAR1 Capital Management, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 369,785 shares valued at US$15.0M — an increase of 117,390 shares quarter over quarter.. Notable position changes include a 250% increase in Q3 2025 (shares rose 17% over the following quarter), a 889% increase in Q1 2026 (shares rose 105% over the following quarter), a 47% increase in Q3 2026 (shares fell 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 10.00K $137.00K New
Q3 2025 35.00K $698.25K Add
Q4 2025 40.00K $936.80K Add
Q1 2026 395.46K $7.11M Add
Q2 2026 252.40K $9.29M Reduce
Q3 2026 369.79K $15.02M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 46 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$184.6M), Kynam Capital Management, LP (US$98.9M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held URGN?

ADAR1 Capital Management, LLC has disclosed URGN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is ADAR1 Capital Management, LLC's current position in URGN?

As of Q3 2026, ADAR1 Capital Management, LLC holds 369.79K shares of URGN (UROGEN PHARMA LTD), valued at $15.02M, representing 0.82% of its reported portfolio and ranking #28.

Has ADAR1 Capital Management, LLC been buying or selling URGN?

In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in URGN. The position peaked in Q3 2026 at 369.79K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.